Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Colorcon
Medtronic
Dow
Boehringer Ingelheim

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Epratuzumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Epratuzumab?

Epratuzumab is an investigational drug.

There have been 26 clinical trials for Epratuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2010.

The most common disease conditions in clinical trials are Lupus Erythematosus, Systemic, Lymphoma, and Leukemia, Lymphoid. The leading clinical trial sponsors are Immunomedics, Inc., UCB Pharma, and Nantes University Hospital.

There are fifty-three US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Epratuzumab
TitleSponsorPhase
Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALLNantes University HospitalPhase 2
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic LeukemiaImmunomedics, Inc.Phase 1/Phase 2
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic LeukemiaInstitut Cancerologie de l'OuestPhase 1/Phase 2

See all Epratuzumab clinical trials

Clinical Trial Summary for Epratuzumab

Top disease conditions for Epratuzumab
Top clinical trial sponsors for Epratuzumab

See all Epratuzumab clinical trials

US Patents for Epratuzumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Epratuzumab   Start Trial Trilayer coated pharmaceutical packaging SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)   Start Trial
Epratuzumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Epratuzumab   Start Trial Chimeric receptors and uses thereof in immune therapy National University of Singapore (Singapore, SG) St. Jude Children's Research Hospital (Memphis, TN) Unum Therapeutics Inc. (Cambridge, MA)   Start Trial
Epratuzumab   Start Trial Targeting of innate immune response to tumor site GAVISH-GALILEE BIO APPLICATIONS, LTD. (Kiryat Shmona, IL) HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (Jerusalem, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Epratuzumab

Drugname Country Document Number Estimated Expiration Related US Patent
Epratuzumab Argentina 082615 2030-08-09   Start Trial
Epratuzumab Australia 2010249031 2030-05-12   Start Trial
Epratuzumab Australia 2010249033 2030-05-12   Start Trial
Epratuzumab Australia 2011252925 2030-05-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
McKesson
Merck
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.